Mesenchymal Stem Cells and Glutathione mitigate methotrexate-induced intestinal mucositis in rats
Background
Chemotherapeutic agents like methotrexate (MTX) are crucial for cancer treatment but often induce severe side effects, notably intestinal mucositis. This condition is characterized by significant oxidative stress, inflammation, and widespread epithelial cell death, leading to compromised gut barrier function and patient discomfort. Current supportive care often falls short in fully mitigating these effects. Mesenchymal stem cells (MSCs) and glutathione (GSH) are being explored for their regenerative, anti-inflammatory, and antioxidant properties, offering potential avenues to protect against chemotherapy-induced tissue damage and improve patient outcomes.
Study Design
Researchers investigated the therapeutic effects of MSCs and GSH on MTX-induced mucositis in 30 adult female Wistar-Albino rats. Animals were divided into five groups (n=6 each). Mucositis was induced by a single intraperitoneal (IP) dose of MTX (45 mg/kg). Treatment groups subsequently received MSCs, GSH, or a combination of both. MSCs were isolated and confirmed for multipotent differentiation capabilities. The study assessed treatment efficacy using histopathological analysis, immunohistochemistry, biochemical assays, and gene expression via RT-qPCR to evaluate mucosal damage, inflammation, apoptosis, and oxidative stress markers.
Results
The MTX-only group exhibited significant mucosal damage, including villus atrophy, epithelial shedding, and increased fibrosis. However, all treatment groups (MSCs, GSH, or combination) demonstrated partial preservation of villus architecture and reduced histopathological damage compared to the MTX group. MTX administration markedly increased inflammatory markers like TNF-α and IL-1β, and the apoptotic marker caspase-3. These elevations were reduced to varying extents following MSC and/or GSH treatment. Additionally, MTX elevated malondialdehyde (MDA) levels and decreased antioxidant enzyme activities. MSC and/or GSH treatments effectively attenuated oxidative stress and improved antioxidant parameters. While the combination of MSCs and GSH attenuated MTX-induced intestinal injury, the abstract noted:
definitive superiority of the combined treatment over monotherapies was not consistently supported by the statistical analyses.
Key Findings
- MTX (45 mg/kg IP) induced significant intestinal mucosal damage, villus atrophy, and epithelial shedding in rats.
- MSCs, GSH, or their combination partially preserved villus architecture and reduced histopathological damage.
- MTX increased inflammatory markers (
TNF-α,IL-1β) and apoptotic marker (caspase-3), which were reduced by treatments. - MTX elevated
MDAand decreased antioxidant enzyme activities; MSC/GSH treatments attenuated oxidative stress. - Combined MSC and GSH treatment attenuated MTX-induced injury, but its superiority over monotherapies was not consistently supported.
Why It Matters
This study highlights the potential of MSCs and GSH as adjunctive therapies to mitigate severe chemotherapy-induced mucositis. For individuals undergoing MTX treatment, this research suggests that incorporating MSCs or GSH could significantly reduce debilitating gastrointestinal side effects, potentially improving treatment adherence and quality of life. While the exact dosing and administration protocols for MSCs and GSH in humans are still far from established, these preclinical findings provide a strong rationale for further translational research. Future clinical protocols for MTX chemotherapy might include co-administration of MSCs or GSH to protect the gut, though more mechanistic studies and human trials are essential to define optimal strategies and confirm efficacy and safety.
methotrexate
mucositis
mesenchymal-stem-cells
glutathione
oxidative-stress
inflammation